Analysts and Calls -- UBS Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Analysts and Calls -- UBS

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who started this subject	12/9/2002 11:58:06 AM
From: Findit	Read Replies (1) of 19

Needham does not agreee with UBS. From today's Business Week Online - >>In response to an analyst downgrade on Friday, Isis Pharmceuticals (ISIS ) says its Affinitak trial remains blinded; the study design prevents insights; its trial database is secure; and analysis and new drug application plans have been finalized. Needham reiterates strong buy. <<

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next